Flying The Web For News.
  • Happy Holidays
    Happy Holidays
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

Details
Category: Globe NewsWire News Distribution Service

Oxford, UK November 19, 2024. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).


Posted: 2024-11-19 08:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | theolytics | doses | patient


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer - Newscast

Ultragenyx Pharmaceutical Inc. Doses First Patient in Pivotal Phase 3 Aspire Study for GTX-102 in Angelman Syndrome

Thu, 19 Dec 2024 13:11:00 GMT The press release includes ... 8 mg loading doses of GTX-102 followed by dosing in a maintenance period that will increase to a maximum dose of 14 mg of GTX-102 quarterly. Patients in the sham ...

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

Mon, 18 Nov 2024 16:01:00 GMT The Phase I/IIa trial is designed to investigate the safety and tolerability of THEO-260 administered via intravenous delivery and determine the recommended Phase II dose ... approach for ovarian ...






Blow Us A Whistle